A.P. Pharma is postponing its target launch date for its lead product, APF530, to the first half of 2014 from the second half of 2013, after receiving a “complete response” letter from FDA for prevention of chemotherapy-induced nausea and vomiting (CINV).
Announced on March 28, the “complete response” letter marks another rejection of the candidate, which is a subcutaneously delivered, long-acting...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?